Target intelligence / Profile preview

Phosphoethanolamine-modified lipid A (PEtn-lipid A) (PEtn-lipid A)

Target
PEtn-lipid A
Molecular classification
Lipid, Lipopolysaccharide, Bacterial outer membrane component
01

Overview

Phosphoethanolamine-modified lipid A is a critical structural variant of the lipid anchor of lipopolysaccharide (LPS) found in the outer membrane of Gram-negative bacteria. This modification is primarily mediated by phosphoethanolamine transferases, such as the plasmid-encoded MCR (mobile colistin resistance) enzymes or chromosomally encoded EptA (Liu et al., 2016, Lancet Infect Dis). The addition of a phosphoethanolamine (PEtn) group to the 1 or 4' phosphate positions of lipid A reduces the overall negative charge of the bacterial cell surface (Gao et al., 2016, Nat Commun). This charge neutralization prevents the binding of cationic antimicrobial peptides (CAMPs) and polymyxin antibiotics, such as colistin and polymyxin B, which rely on electrostatic interactions to disrupt the membrane (Poirel et al., 2017, Clin Microbiol Rev). As a result, these modified lipids are a major determinant of high-level resistance to last-resort antibiotics in pathogens like Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii. Targeting the enzymes responsible for this modification or developing drugs that bypass this charge-shielding mechanism are active areas of antimicrobial research.

Other names
Phosphoethanolamine-modified lipopolysaccharidepEtn-lipid ApEtn-LPSMCR-modified lipid APhosphoethanolamine-modified bacterial outer membrane
02

Mechanism of action

Polymyxins bind to the negatively charged phosphate groups of lipid A; phosphoethanolamine modification reduces this negative charge, preventing drug binding and subsequent membrane disruption (Baron et al., 2016, J Antimicrob Chemother).

03

Biological functions

Membrane integrityResistance to cationic antimicrobial peptidesSurface charge modulationBacterial cell wall stabilization
04

Disease associations

Gram-negative bacterial infectionMultidrug-resistant infectionSepsis
05

Safety considerations

Nephrotoxicity of interacting polymyxinsNeurotoxicity of interacting polymyxinsRapid global spread of plasmid-mediated resistance (mcr genes)Narrow therapeutic index of drugs targeting this pathway
06

Interacting drugs

Colistin (Polymyxin E)

1 more in the full profile.

07

Biomarkers

mcr-1 genemcr-2 genemcr-3 to mcr-10 genesColistin resistance phenotype (MIC > 2 mg/L)

Beyond the preview

Go deeper on Phosphoethanolamine-modified lipid A (PEtn-lipid A) (PEtn-lipid A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphoethanolamine-modified lipid A (PEtn-lipid A) (PEtn-lipid A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call